Jing Xie

Dr. Jing Xie


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2021 in Molecules
Verified
Journal Article
Open access
PDF file
DLDiedie Li
Diedie Li
CGChengzhi Gao
Chengzhi Gao
MKMeiyan Kuang
Meiyan Kuang
MXMinhao Xu
Minhao Xu
BWBen Wang
Ben Wang
JXJing Xie
Jing Xie
RNA interference (RNAi) can mediate gene-silencing by knocking down the expression of a target gene via cellular machinery with much higher efficiency in contrast to other antisense-based approaches which represents an emerging therapeutic strategy for combating cancer. Distinct characters of nanoparticles, such as distinctive size, are fundamental for the efficient delivery of RNAi therapeutics, allowing for higher targeting and safety. In this review, we present the mechanism of RNAi and briefly describe the hurdles and concerns of RNAi as a cancer treatment approach in systemic delivery. Furthermore, the current nanovectors for effective tumor delivery of RNAi therapeutics are classified, and the characteristics of different nanocarriers are summarized.

4 November 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
YTYaqin Tang
Yaqin Tang
QLQiyu Li
Qiyu Li
ZZZiwei Zhou
Ziwei Zhou
HBHuayang Bai
Huayang Bai
NXNianting Xiao
Nianting Xiao
LCLi Chong
Li Chong
Gas therapy has emerged as a promising approach for treating cancer, with gases like NO, H2S, and CO showing positive effects. Among these, NO is considered a key gas molecule with significant potential in stopping cancer progression. However, due to its high reactivity and short half-life, delivering NO directly to tumors is crucial for enhancing cancer treatment. NO-driven nanomedicines (NONs) have been developed to effectively deliver NO donors to tumors, showing great progress in recent years. This review provides an overview of the latest advancements in NO-based cancer nanotherapeutics. It discusses the types of NO donors used in current research, the mechanisms of action behind NO therapy for cancer, and the different delivery systems for NO donors in nanotherapeutics. It also explores the potential of combining NO donors with other treatments for enhanced cancer therapy. Finally, it examines the future prospects and challenges of using NONs in clinical settings for cancer treatment.

5 September 2022 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
CGChengzhi Gao
Chengzhi Gao
LZLanfang Zhang
Lanfang Zhang
MXMinhao Xu
Minhao Xu
YLYi Luo
Yi Luo
BWBen Wang
Ben Wang
JXJing Xie
Jing Xie

7 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YTyaqin tang
yaqin tang
XLXingyou Liu
Xingyou Liu
MSMeng Sun
Meng Sun
SXSu Xiong
Su Xiong
NXNianting Xiao
Nianting Xiao
JXJing Xie
Jing Xie
Extracellular vesicles (EVs) are small, membrane-based vesicles released by cells that play a critical role in various physiological and pathological processes. They act as vehicles for transporting a variety of endogenous cargo molecules, enabling intercellular communication. Due to their natural properties, EVs have emerged as a promising “cell-free therapy” strategy for treating various diseases, including cancer. They serve as excellent carriers for different therapeutics, including nucleic acids, proteins, small molecules, and other nanomaterials. Modifying or engineering EVs can improve the efficacy, targeting, specificity, and biocompatibility of EV-based therapeutics for cancer therapy. In this review, we comprehensively outline the biogenesis, isolation, and methodologies of EVs, as well as their biological functions. We then focus on specific applications of EVs as drug carriers in cancer therapy by citing prominent recent studies. Additionally, we discuss the opportunities and challenges for using EVs as pharmaceutical drug delivery vehicles. Ultimately, we aim to provide theoretical and technical support for the development of EV-based carriers for cancer treatment.

Verified
Journal Article
Open access
PDF file
LBLu Bai
Lu Bai
LYLeijie Yu
Leijie Yu
MRMengqiong Ran
Mengqiong Ran
XZXing Zhong
Xing Zhong
MSMeng Sun
Meng Sun
JXJing Xie
Jing Xie
Exosomes, which are nano-sized natural vesicles secreted by cells, are crucial for intercellular communication and interactions, playing a significant role in various physiological and pathological processes. Their characteristics, such as low toxicity and immunogenicity, high biocompatibility, and remarkable drug delivery capabilities—particularly their capacity to traverse the blood–brain barrier—make exosomes highly promising vehicles for drug administration in the treatment of brain disorders. This review provides a comprehensive overview of exosome biogenesis and isolation techniques, strategies for the drug loading and functionalization of exosomes, and exosome-mediated blood–brain barrier penetration mechanisms, with a particular emphasis on recent advances in exosome-based drug delivery for brain disorders. Finally, we address the opportunities and challenges associated with utilizing exosomes as a drug delivery system for the brain, summarizing the barriers to clinical translation and proposing future research directions.

Verified
Journal Article
Open access
PDF file
MXMinhao Xu
Minhao Xu
LZLanfang Zhang
Lanfang Zhang
YGyue guo
yue guo
LBLu Bai
Lu Bai
YLYi Luo
Yi Luo
JXJing Xie
Jing Xie
Lung cancer is a leading cause of cancer mortality worldwide, with a 5-year survival rate of less than 20%. Gambogic acid (GA) is a naturally occurring and potent anticancer agent that destroys tumor cells through multiple mechanisms. According to the literature, one of the most potent inhibitors of caspases and apoptosis currently known is the X-linked Inhibitor of Apoptosis Protein (XIAP). It is highly expressed in various malignancies but has little or no expression in normal cells, making it an attractive target for cancer treatment. Here we report the development of a chitosan (CS)-based cationic nanoemulsion-based pulmonary delivery (p.d.) system for the co-delivery of antineoplastic drugs (GA) and anti-XIAP small interfering RNA (siRNA). The results showed that the chitosan-modified cationic nanoemulsions could effectively encapsulate gambogic acid as well as protect siRNA against degradation. The apoptosis analysis confirmed that the cationic nanoemulsions could induce more apoptosis in the A549 cell line. In addition, most drugs and siRNAs have a long residence time in the lungs through pulmonary delivery and show greater therapeutic effects compared to systemic administration. In summary, this work demonstrates the applicability of cationic nanoemulsions for combined cancer therapy and as a promising approach for the treatment of lung cancer.